Regeneron co-chief scientific officer exercises options and sells shares
Regeneron Pharmaceuticals co-chief scientific officer Andrew J. Murphy exercised 17,000 stock options on October 13 and sold 4,147 shares on October 14. The trades occurred under a pre-approved trading plan, reflecting a standard schedule to cover tax obligations and exercise option rights.
Key points
- On October 13, Andrew J. Murphy exercised 17,000 company stock options.
- Stock sales under a pre-approved Rule 10b5-1 plan should not be interpreted as an assessment of the company’s prospects or a loss of executive confidence.
Insider transaction details
On October 13, Andrew J. Murphy exercised 17,000 company stock options. The company withheld 12,853 shares to cover taxes and the cost of exercising the options, a standard procedure for such transactions.
The following day, October 14, Andrew J. Murphy sold 4,147 shares on the open market at a weighted average price of $772.6973. The sale occurred under a Rule 10b5-1 plan, a preset selling schedule executives set up in advance to avoid suspicions of using non-public information. This plan was adopted on May 7, 2026.
What these sales mean
Stock sales under a pre-approved Rule 10b5-1 plan should not be interpreted as an assessment of the company’s prospects or a loss of executive confidence. Such transactions are often executed automatically according to previously scheduled dates or price levels, rather than due to sudden business changes.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Regeneron Pharmaceuticals
A notification in your browser or on your phone when we publish about Regeneron Pharmaceuticals. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
